Wall Street brokerages expect ABIOMED, Inc. (NASDAQ:ABMD) to post earnings per share (EPS) of $0.50 for the current fiscal quarter, according to Zacks. Five analysts have made estimates for ABIOMED’s earnings, with the highest EPS estimate coming in at $0.58 and the lowest estimate coming in at $0.46. ABIOMED posted earnings per share of $0.34 during the same quarter last year, which would indicate a positive year-over-year growth rate of 47.1%. The company is scheduled to announce its next quarterly earnings results on Thursday, January 25th.

According to Zacks, analysts expect that ABIOMED will report full-year earnings of $2.40 per share for the current financial year, with EPS estimates ranging from $2.21 to $2.59. For the next financial year, analysts expect that the company will post earnings of $2.61 per share, with EPS estimates ranging from $2.26 to $3.10. Zacks’ EPS calculations are a mean average based on a survey of analysts that follow ABIOMED.

ABIOMED (NASDAQ:ABMD) last released its quarterly earnings data on Thursday, October 26th. The medical equipment provider reported $0.54 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.16. The company had revenue of $132.80 million for the quarter, compared to the consensus estimate of $131.18 million. ABIOMED had a return on equity of 13.89% and a net margin of 18.27%. The company’s quarterly revenue was up 28.9% on a year-over-year basis. During the same period in the previous year, the business earned $0.20 earnings per share.

ABMD has been the topic of several recent analyst reports. Zacks Investment Research raised ABIOMED from a “hold” rating to a “buy” rating and set a $220.00 target price on the stock in a report on Tuesday, November 7th. SunTrust Banks reissued a “buy” rating and issued a $195.00 target price on shares of ABIOMED in a report on Wednesday, November 1st. Jefferies Group boosted their target price on ABIOMED from $175.00 to $208.00 and gave the stock a “buy” rating in a report on Friday, September 29th. Piper Jaffray Companies reissued a “buy” rating and issued a $160.00 target price on shares of ABIOMED in a report on Tuesday, August 29th. Finally, BidaskClub downgraded ABIOMED from a “buy” rating to a “hold” rating in a report on Saturday, August 26th. Three analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $190.43.

In other news, VP Andrew J. Greenfield sold 11,282 shares of the business’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $169.32, for a total value of $1,910,268.24. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, VP Michael G. Howley sold 10,000 shares of the company’s stock in a transaction on Monday, October 30th. The stock was sold at an average price of $178.64, for a total value of $1,786,400.00. Following the transaction, the vice president now directly owns 56,757 shares in the company, valued at approximately $10,139,070.48. The disclosure for this sale can be found here. Insiders sold a total of 27,646 shares of company stock worth $4,836,333 over the last three months. 7.00% of the stock is owned by company insiders.

A number of large investors have recently bought and sold shares of ABMD. Seven Eight Capital LP acquired a new position in ABIOMED during the 2nd quarter worth $100,000. Rehmann Capital Advisory Group acquired a new position in ABIOMED during the 3rd quarter worth $202,000. Sigma Planning Corp acquired a new position in ABIOMED during the 3rd quarter worth $206,000. Dorsey & Whitney Trust CO LLC acquired a new position in ABIOMED during the 3rd quarter worth $215,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in ABIOMED by 15.0% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,511 shares of the medical equipment provider’s stock worth $217,000 after buying an additional 197 shares in the last quarter. 90.92% of the stock is currently owned by hedge funds and other institutional investors.

ABIOMED (ABMD) traded down $4.62 during midday trading on Thursday, reaching $188.44. The company’s stock had a trading volume of 292,909 shares, compared to its average volume of 337,798. The firm has a market capitalization of $8,560.00, a P/E ratio of 123.68, a price-to-earnings-growth ratio of 2.57 and a beta of 0.15. The company has a quick ratio of 5.20, a current ratio of 5.84 and a debt-to-equity ratio of 0.02. ABIOMED has a 12 month low of $103.53 and a 12 month high of $200.28.

COPYRIGHT VIOLATION WARNING: “$0.50 Earnings Per Share Expected for ABIOMED, Inc. (ABMD) This Quarter” was posted by American Banking News and is the property of of American Banking News. If you are accessing this story on another site, it was illegally copied and republished in violation of international copyright law. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/12/14/0-50-earnings-per-share-expected-for-abiomed-inc-abmd-this-quarter.html.

About ABIOMED

ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.

Get a free copy of the Zacks research report on ABIOMED (ABMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.